The application of chatbots in perinatal mental health interventions: a scoping review protocol.

Ovarian cancer ranks as the third most prevalent and the most lethal malignant neoplasm of the female reproductive system []. Despite clinical remission with standard surgery and platinum-based chemotherapy, approximately 70% of patients experience recurrence, with a 5-year overall survival rate below 30% []. To address this, first-line maintenance therapy — long-term systemic treatment given to extend progression-free survival in patients achieving complete or partial response (CR/PR) following upfront platinum-based chemotherapy — has become a key component of ovarian cancer treatment in recent years []. Currently, first-line maintenance therapy for ovarian cancer has entered the targeted treatment era, primarily utilizing poly(ADP-ribose) polymerase (PARP) inhibitors and anti-angiogenic agents []. Clinical studies have confirmed that PARP inhibitors significantly prolong progression-free survival in ovarian cancer, while bevacizumab exerts notable efficacy by inhibiting tumor angiogenesis [, , ]. The widespread adoption of targeted therapy has shifted ovarian cancer management from intermittent post-recurrence treatment to long-term chronic disease care []. However, while first-line maintenance therapy markedly extends ovarian cancer patients’ survival, the adverse effects associated with long-term administration of this maintenance regimen have garnered widespread attention. Patients undergoing first-line maintenance therapy may suffer from diverse symptoms, including sleep disorders, emotional disturbances, fatigue, and abdominal discomfort [, ]. Without timely and effective clinical intervention, these symptoms can worsen psychological distress, reduce treatment adherence, and even adversely impact survival outcomes [].